奈玛特韦片/利托那韦片与心血管药物合用情况及潜在用药风险干预  

Combination of nimatrelvir/ritonavir tablets with cardiovascular drugs and potential medication risk interventions

作　　者：周洋[1] 刘楠楠[2] 彭文星[1] 林阳[1] 石秀锦[1] ZHOU Yang;LIU Nan-nan;PENG Wen-xing;LIN Yang;SHI Xiu-jin(Department of Pharmacy,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China;Department of Pharmacy,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京安贞医院药事部,北京100029 [2]中日友好医院药学部,北京100029

出　　处：《临床药物治疗杂志》2023年第5期76-80,共5页Clinical Medication Journal

摘　　要：目的了解首都医科大学附属北京安贞医院患者奈玛特韦片/利托那韦片联合心血管药物应用特征,为规范临床合理用药提供参考。方法选取2022年12月至2023年1月该院使用奈玛特韦片/利托那韦片同时合用心血管系统药物的患者,对联合用药、相互作用等进行统计分析。结果共纳入147例患者,合并心血管系统药物13类,共48种药物,其中与奈玛特韦片/利托那韦片存在潜在相互作用的药物25种,临床药师为其中90例患者提供个体化药物调整建议。结论心血管疾病患者使用的心血管药物种类比较广泛,且普遍与奈玛特韦片/利托那韦片存在潜在相互作用,潜在用药风险高,医师和药师应重视并及时调整治疗方案,加强监测。Objective To investigate the application characteristics of concomitant use of nirmatrelvir/ritonavir tablets and cardiovascular drugs,thus to provide reference for regulating clinical drug use.Methods Patients who used nirmatrelvir/ritonavir tablets and cardiovascular drugs simultaneously at Beijing Anzhen Hospital,Capital Medical University,from Decem⁃ber 2022 to January 2023 were selected.Statistical analysis was performed on the drug combination and drug interactions.Results A total of 147 patients were included,involving 13 categories and 48 kinds of cardiovascular drugs.Among them,25 drugs had interactions with nirmatrelvir/ritonavir tablets.Clinical pharmacists provided individualized drug adjustment advice for 90 patients.Conclusions Cardiovascular patients use a wide range of cardiovascular drugs that have potential interactions with nirmatrelvir/ritonavir tablets,resulting high medicaiton risk.Physicians and pharmacists should pay attention to the risk,immediately adjust the treatment plan,and strengthen monitoring.

关 键 词：新型冠状病毒感染 奈玛特韦片/利托那韦片 心血管药物 药物相互作用 潜在用药风险 

分 类 号：R978.5[医药卫生—药品] R969.3[医药卫生—药学]